Skip to content

An Exploratory Randomized Controlled Trial of Acupuncture Combined with Cognitive Training for Mild to Moderate Alzheimer's Disease Patients

An Exploratory Randomized Controlled Trial of Acupuncture Combined with Cognitive Training for Mild to Moderate Alzheimer's Disease Patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000200
Enrollment
Unknown
Registered
2025-01-28
Start date
2024-06-03
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Interventions

Simple acupuncture group:acupuncture
acupuncture combined with cognitive training group:acupuncture combined with cognitive training
fake acupuncture group:fake acupuncture

Sponsors

Guang 'anmen Hospital China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. In line with the NIA-AA standard is likely to be AD standard; 2. 50 years = age =85 years; 3. 0.5 score = clinical dementia rating score =2 score; 4. Hachinski Ischemia Scale score =4 points; 5.Sign informed consent and participate in the experiment voluntarily; 6. If the subject is capable of making a decision he/she will sign the informed consent; If the subject has the ability to make decisions but cannot sign informed consent due to low educational level after obtaining the consent of the subject a witness must witness the process of informed consent and sign the informed consent as a witness; If the subject does not have the ability to make informed consent he/she should obtain informed consent from his/her legal representative. 7. Able to follow instructions without any hearing or visual impairment.

Exclusion criteria

Exclusion criteria: 1.Accompanied by severe cerebrovascular disease; 2.With other diseases that can cause cognitive dysfunction or progressive memory impairment; 3.Drug-induced cognitive dysfunction or progressive memory impairment; 4.Patients with severe cardiovascular diseases malignant tumors and severe hepatic and renal insufficiency; 5.Patients with severe fear of needles faintness and severe skin infection; 6.Patients who are highly dependent on care facilities; 7.Patients who received acupuncture treatment and cognitive training in the last 2 weeks; 8.Participants who simultaneously participating in other clinical trials upon the enrollment.

Design outcomes

Primary

MeasureTime frame
Alzheimers disease assessment scale cognition ADAS-Cog;

Secondary

MeasureTime frame
Clinician Interview–Based Impression of Change scale CIBIC;Treatment Satisfaction Survey;Zarit Caregiving Burden Scale ZBI;Neuropsychiatric Questionnaire Patient Score;Neuropsychiatric Questionnaire Nursing Distress Score;Activities of Daily Living ADL;

Countries

China

Contacts

Public ContactJiaBaohui

Guang 'anmen Hospital China Academy of Chinese Medical Sciences

myrroossee@aliyun.com13520090050

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026